Barclays
RXII

Barclays’s GALENA BIOPHARMA INC COM RXII Stock Holding History

Barclays’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,700
Closed -$1K – 7113
2016
Q3 		$1K Buy
1,700
+1,685
+11,233% +$991 ﹤0.01% 6558
2016
Q2 		$0 Sell
15
-395
-96% – ﹤0.01% 6993
2016
Q1 		$0 Buy
410
+395
+2,633% – ﹤0.01% 6855
2015
Q4 		$0 Sell
15
-830
-98% – ﹤0.01% 7262
2015
Q3 		$1K Sell
845
-2,253
-73% -$2.67K ﹤0.01% 6774
2015
Q2 		$3K Sell
3,098
-872
-22% -$844 ﹤0.01% 6765
2015
Q1 		$4K Sell
3,970
-5,616
-59% -$5.66K ﹤0.01% 6749
2014
Q4 		$10K Sell
9,586
-9,851
-51% -$10.3K ﹤0.01% 6760
2014
Q3 		$38K Sell
19,437
-7,444
-28% -$14.6K ﹤0.01% 6091
2014
Q2 		$81K Sell
26,881
-22,617
-46% -$68.2K ﹤0.01% 5583
2014
Q1 		$99K Sell
49,498
-1,294
-3% -$2.59K ﹤0.01% 5467
2013
Q4 		$203K Buy
50,792
+32,216
+173% +$129K ﹤0.01% 5001
2013
Q3 		$38K Buy
18,576
+14,195
+324% +$29K ﹤0.01% 6220
2013
Q2 		$10K Buy
+4,381
New +$10K ﹤0.01% 7165

Barclays's RXII Position: Q4 2016 in Review

Barclays sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,700 shares — an estimated $1K sold.

Barclays first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $203K in Q4 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.

  • Barclays reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
  • Barclays sold 1,700 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $1K.
  • Barclays first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
  • Barclays's GALENA BIOPHARMA INC COM position peaked at $203K in Q4 2013.
  • 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.